Other invasive malignancy =<  years prior to registration; exceptions are colonic polyps, non-melanoma skin cancer, ductal carcinoma in situ, bladder carcinoma in situ, or carcinoma-in-situ of the cervix
History of other malignancy within the last  years, except for appropriately treated carcinoma in situ of the cervix, non-melanoma skin carcinoma, or other malignancy with a similar expected curative outcome
Malignancy other than melanoma within  years of enrollment except for: adequately treated (i.e., with curative intent) basal or squamous cell carcinoma, in situ carcinoma of the cervix, in situ ductal adenocarcinoma of the breast, in situ prostate cancer, or limited stage bladder cancer.
A history of other malignancy =<  years previous; exceptions are malignancies with a negligible risk of metastasis or death (e.g., expected -year overall survival [OS] > %) that were treated with an expected curative outcome, such as squamous cell carcinoma of the skin, in-situ carcinoma of the cervix uteri, non-melanomatous skin cancer, carcinoma in situ of the breast, incidental histological finding of prostate cancer (tumor, node, metastasis [TNM] stage of Ta or Tb) or synchronous head and neck (H&N) primaries
History of other malignancy within the last  years, except for appropriately treated carcinoma in situ of the cervix, non-melanoma skin carcinoma, or other malignancy with a similar expected curative outcome.
History of other malignancy within  years prior to screening, with the exception of those with a negligible risk of metastasis or death, such as adequately treated carcinoma in situ of the cervix, non-melanoma skin carcinoma, localized prostate cancer, ductal carcinoma in situ, or Stage I uterine cancer
Other malignancies treated within the last  years, except in situ cervix carcinoma or non-melanoma skin cancer.
History of prior invasive malignancy diagnosed within  years prior to study enrollment; exceptions are malignancies with a negligible risk of metastasis or death (e.g., expected -year OS > %) that were treated with an expected curative outcome, such as squamous cell carcinoma of the skin, in-situ carcinoma of the cervix uteri, non-melanomatous skin cancer, carcinoma in situ of the breast, or incidental histological finding of prostate cancer (TNM stage of Ta or Tb)
History of another invasive malignancy unless treated with curative intent  years or more prior to study entry; patients with localized carcinoma of the cervix, non-melanoma skin cancer, or early stage prostate cancer requiring observation only are eligible regardless of timing of diagnosis
History of other malignancy =<  years prior to registration except for non-melanoma skin cancer, carcinoma in situ of the cervix, and ductal carcinoma in situ (DCIS)
Pior history of treated malignancy in the past  years. Subjects with non-melanoma skin cancer, localized prostate cancer, and carcinoma in situ of the breast of cervix are allowed.
Patients with other prior malignancies must have had a >= -year disease-free interval, except for: in situ carcinoma of the cervix, in situ ductal carcinoma of the breast, in situ prostate cancer, in situ bladder cancer; these must have been deemed stable and not expected to relapse; in addition, early stage skin cancers, including basal, squamous cell cutaneous carcinoma, and melanoma, are permitted if previously treated with curative intent and not expected to relapse
Other known co-existing malignancies except non-melanoma skin cancer and carcinoma in situ of the uterine cervix, unless definitively treated and proven no evidence of recurrence for  years
Patient has a history of other malignancies within the last  years, except for non-melanoma skin cancer or carcinoma in situ of the cervix
Malignancies other than RCC within  years of first study treatment with the exception of those with negligible risk of metastases or death and/or treated with expected curative outcome (carcinoma in situ of the cervix, basal or squamous cell skin cancer, localized prostate cancer, ductal carcinoma in situ of the breast, non-muscle invasive urothelial carcinoma)
Patients with other malignancies within  years from enrollment, with the exception of non-melanoma skin cancer, cervix in situ
Patients with invasive malignancy other than melanoma at the time of enrollment and within  years of screening are excluded, except for: adequately treated (i.e. with curative intent) basal or squamous cell carcinoma, in situ carcinoma of the cervix, in situ ductal adenocarcinoma of the breast, in situ prostate cancer, or limited stage bladder cancer or other any other cancers from which the patient has been disease-free for at least  years
Malignancies other than RCC within  years of first study treatment with the exception of those with negligible risk of metastases or death (carcinoma in situ of the cervix, basal or squamous cell skin cancer, localized prostate cancer, ductal carcinoma in situ of the breast, non-muscle invasive urothelial carcinoma)
History of other malignancy =<  years prior to registration except for non-melanoma skin cancer, carcinoma in situ of the cervix, and ductal carcinoma in situ (DCIS)
Previous or active non-melanoma malignancies (excluding non-melanoma skin cancer or carcinoma in situ of the cervix) diagnosed/treated within the last  years
Patients with other active, current primary malignancies, other than carcinoma in situ of the cervix or non-melanoma skin cancer
No prior malignancies within  years, unless treated early stage breast cancer, treated carcinoma in situ of the cervix, resected skin malignancies, or treated prostate cancer
Patient with a history of other malignancies within the last  years, except for nonmelanoma skin cancer or carcinoma in situ of the cervix.
HPV-ASSOCIATED OROPHARYNX SQUAMOUS CELL CARCINOMA: Patients with a history of a curatively treated malignancy must be disease-free for at least two years except for carcinoma in situ of cervix, melanoma in-situ (if fully resected), and/or non-melanomatous skin cancer
Other malignancy within the last  years except: adequately treated non-melanoma skin cancer, curatively treated in situ cancer of the cervix, ductal carcinoma in situ (DCIS), stage , grade  endometrial carcinoma, or other solid tumors.
Patients with invasive malignancy other than melanoma at the time of enrollment and within  years prior to the first TIL administration are excluded, except for adequately treated (with curative intent) basal or squamous cell carcinoma, in situ carcinoma of the cervix, in situ ductal adenocarcinoma of the breast, in situ prostate cancer, or limited stage bladder cancer or other cancers from which the patient has been disease-free for at least  years
Patients with invasive malignancy other than melanoma at the time of enrollment and within  years prior to the first vemurafenib administration are excluded, except for adequately treated (with curative intent) basal or squamous cell carcinoma of the skin, in situ carcinoma of the cervix, in situ ductal adenocarcinoma of the breast, in situ prostate cancer, or limited stage bladder cancer or other cancers from which the patient has been disease-free for at least  years
Subject has any other malignancy within  years prior to randomization. Exceptions include the following: squamous cell carcinoma of the skin, in-situ carcinoma of the cervix, uteri, non-melanomatous skin cancer, carcinoma in situ of the breast, or incidental histological finding of prostate cancer (TNM stage of Ta or Tb)  all treatments that should have been completed  months prior to signing ICF.
No other cancer requiring therapy within the last  years (except in situ carcinoma or nonmelanoma skin cancer)
Malignancies other than NSCLC within  years prior to enrollment, with the exception of those with a negligible risk of metastasis or death (such as adequately treated carcinoma in-situ of the cervix, basal or squamous cell skin cancer, localized prostate cancer, or ductal carcinoma in situ).
History of other malignancy within the previous  years, except for appropriately treated carcinoma in situ of the cervix, non-melanoma skin carcinoma, Stage I uterine cancer, or participants who have undergone potentially curative therapy with no evidence of disease and are deemed by the treating physician to be at low risk for recurrence
Subjects who have any history of other malignancy (except non-melanoma skin carcinoma and carcinoma-in-situ of the uterine cervix) within  years of study entry.
Other active malignancy =<  years prior to registration; EXCEPTIONS: non-melanoma skin cancer, prostatic intraepithelial neoplasia without evidence of prostate cancer, lobular carcinoma in situ in one breast, or carcinoma-in-situ of the cervix that has been treated
Other malignancies within the past  years other than non-melanoma superficial skin cancer or carcinoma in situ of the cervix
History of other malignancy within the last  years except for appropriately treated carcinoma in situ of the cervix, non-melanoma skin carcinoma, Stage I uterine cancer, or other non-breast malignancies with a similar outcome to those mentioned above
History of other malignancy in the past  years except carcinoma in situ of the cervix or bladder, non-melanomatous skin cancer or localized/early stage prostate cancer
Invasive malignancy within the past  years prior to first study drug administration, except for adequately treated (with curative intent) basal or squamous cell carcinoma, melanoma, in situ carcinoma of the cervix, in situ ductal adenocarcinoma of the breast, in situ prostate cancer, or limited stage bladder cancer or other cancers from which the patient has been disease-free for at least  years
Other cancer except that for which the transplant was done <  years before study entry, except non-melanoma skin cancer or carcinoma in situ of the uterine cervix or breast
History of a previous invasive malignancy within the last  years, except adequately treated non-melanoma skin cancer, papillary carcinoma of the thyroid or carcinoma in situ of the uterine cervix
Other known co-existing malignancies except non-melanoma skin cancer and carcinoma in situ of the uterine cervix, unless definitively treated and proven no evidence of recurrence for  years.
Patients with other untreated, current primary malignancies, other than carcinoma in situ of the cervix or non-melanoma skin cancer
Patients with non-melanomatous skin cancer, in situ carcinoma, or low-risk prostate cancer can be enrolled.
Diagnosis of other malignancies within the last  years other than curatively treated non-melanoma skin cancer, carcinoma in situ of the cervix, organ-confined or treated non-metastatic prostate cancer, in situ breast carcinoma after complete surgical resection, or superficial transitional cell bladder carcinoma
History of other malignancies within  years prior to enrollment except for tumors with a negligible risk for metastasis or death, such as adequately controlled basal cell carcinoma, squamous-cell carcinoma of the skin, carcinoma in situ of the cervix, early-stage bladder cancer, or low-grade endometrial cancer\r\n* Malignancies that have undergone a putative surgical cure (i.e., localized prostate cancer post-prostatectomy) within  years prior to enrollment may be discussed with the lead primary investigator
Concomitant malignancies except carcinoma in situ, basal or squamous cell skin carcinoma; low grade prostate cancer treated with prostatectomy more than  years ago; early stage melanoma treated with complete surgical excision more than  years ago; carcinoma in situ of cervix treated with cone procedure more than  years ago
History of other malignancy within  years prior to screening, except for appropriately treated carcinoma in situ of the cervix, non-melanoma skin carcinoma, or Stage I uterine cancer
History of other malignancy within the previous  years except for appropriately\n             treated carcinoma in situ of the cervix, non-melanoma skin carcinoma, Stage I uterine\n             cancer, or other malignancies with an expected curative outcome
Subjects who have had a prior malignancy other than carcinoma in situ of the cervix, or nonmelanoma skin cancer
Subject has any other malignancy within  years prior to signing the ICF. Exceptions include the following: squamous cell carcinoma of the skin, in-situ carcinoma of the cervix, uteri, non-melanomatous skin cancer, carcinoma in situ of the breast, or incidental histological finding of prostate cancer (Tumor, node and metastasis (TNM) stage of Ta or Tb). All treatment should have been completed  months prior to signing ICF.
History of, or current brain metastasis. Any other malignancy within  years prior to randomization with the exception of adequately treated in situ carcinoma of the cervix, uteri, or non-melanomatous skin cancer (all treatment of which should have been completed  months prior to enrollment), in situ squamous cell carcinoma of the breast, or incidental prostate cancer.
Other malignancy within the last  years, except for adequately treated or controlled carcinoma in situ of the cervix or skin cancer or primary endometrial cancer of stage </= B.
History of another malignancy within the previous  years, except for appropriately treated and presumed cured carcinoma in situ of the cervix, non-melanoma skin carcinoma, Stage  uterine cancer, and localized prostate cancer
Malignancies other than breast cancer within  years prior to treatment initiation (except for appropriately treated carcinoma in situ of the cervix, non-melanoma skin carcinoma, or Stage I uterine cancer)
Other than ovarian cancer, the patient has been diagnosed or treated for invasive cancer less than  years prior to study enrollment. Patients with cervical carcinoma in situ, non melanomatous skin cancer, and ductal carcinoma in situ definitively treated are allowed.
History of other malignancy within the last  years, except for carcinoma in situ of the cervix, non-melanoma skin carcinoma, Stage  uterine cancer, or cancers with a similar curative outcome as those mentioned above
History of other malignancy within the previous  years, except for appropriately treated carcinoma in situ of the cervix, non-melanoma skin carcinoma, Stage I uterine cancer, or patients who have undergone potentially curative therapy with no evidence of disease and are deemed by the treating physician to be at low risk for recurrence
Malignancy other than breast carcinoma (phase II), except for non-melanoma skin cancer or curatively treated carcinoma in situ of the cervix, diagnosed during the past five years
History of other malignancy within  years prior to screening with the exception of malignancies with a negligible risk of metastasis or death, such as adequately treated carcinoma in situ of the cervix, non-melanoma skin carcinoma, localized prostate cancer, ductal carcinoma in situ, or Stage I uterine cancer
History of other malignancy within  years, except for treated carcinoma in situ of the cervix, non-melanoma skin carcinoma, or Stage I uterine cancer
Malignancies other than RCC within  years of first study treatment with the exception of those with negligible risk of metastases or death (included but not limited to carcinoma in situ of the cervix, basal or squamous cell skin cancer, localized prostate cancer, ductal carcinoma in situ of the breast, non-muscle invasive urothelial carcinoma, or other malignancy not deemed to impact that patients -year life expectancy)
Other cancer except that for which the transplant was done <  years before study entry, except non-melanoma skin cancer or carcinoma in situ of the uterine cervix or breast
Other malignancies within  years prior to enrollment, with the exception of carcinoma in situ of the cervix, basal or squamous cell skin cancer, localized prostate cancer, or ductal carcinoma in situ
Malignancies other than ACC, non-urothelial bladder/upper tract cancer, nonadenocarcinoma prostate cancer, penile cancer or treatment refractory germ-cell tumor within  years of first study treatment with the exception of those with negligible risk of metastases or death and/or treated with expected curative outcome (carcinoma in situ of the cervix, basal or squamous cell skin cancer, localized prostate cancer for patients with malignancies other than non-adenocarcinoma of the prostate, ductal carcinoma in situ of the breast, non muscle invasive urothelial carcinoma of the bladder for patients with malignancies other than non-urothelial bladder cancer)
Other primary or recurrent invasive cancer within the last  years (other than nonmelanomic skin cancer or carcinoma of the cervix in situ)
Other prior malignancy, active within  years, except for localized prostate cancer, cervical carcinoma in situ, non-melanomatous carcinoma of the skin, stage  differentiated thyroid cancer or ductal carcinoma in situ of the breast.
Patients must not have any history of other cancer within  years from registration with the exception of in situ carcinoma of the cervix, in situ carcinoma of the breast or completely resected non-melanoma skin cancer